-
公开(公告)号：WO2021222875A1
公开(公告)日：2021-11-04
申请号：PCT/US2021/030362
申请日：2021-04-30
IPC分类号： A61K31/4162 , A61K31/519 , C07D401/14 , A61P7/06
摘要： The invention relates to methods of treating multiple osteochondroma and anemia resulting from iron imbalance using small molecule ALK2 inhibitors.
-
公开(公告)号：WO2021189019A1
公开(公告)日：2021-09-23
申请号：PCT/US2021/023353
申请日：2021-03-19
发明人： SEEHRA, Jasbir, S. , LACHEY, Jennifer , TSENG, Claire , O'NEILL, Jason , THØGERSEN, Henning , FURUTANI, Elissa
摘要： The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and/or pulmonary hypertension.
-
公开(公告)号：WO2020086730A1
公开(公告)日：2020-04-30
申请号：PCT/US2019/057679
申请日：2019-10-23
IPC分类号： C07K16/28 , C07K16/18 , A61K39/395
摘要： The invention features ALK2 antibodies and antigen binding fragments thereof (e.g., ALK2 binding fragments). The invention also features pharmaceutical compositions and methods of using the ALK2 antibodies or antigen binding fragments thereof to treat bone disease or damage, low red blood cell levels (e.g., anemia or blood loss), heterotopic ossification (e.g., heterotopic ossification resulting from fibrodysplasia ossificans progressiva), Sjogren's syndrome (e.g., dry eye associated with Sjogren's syndrome), multiple osteochondroma, diffuse intrinsic pontine glioma, posterior capsule opacification, or cardiac hypertrophy and/or cardiac fibrosis.
-
公开(公告)号：WO2023081212A1
公开(公告)日：2023-05-11
申请号：PCT/US2022/048703
申请日：2022-11-02
摘要： The invention relates to methods of treating functional iron deficiency (FID) associated with low, very low, or intermediate risk myelodysplastic syndromes, FID associated with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF), and FID associated with myelodysplastic syndromes/myeloproliferative neoplasm (MPN) overlap syndromes using small molecule ALK2 inhibitors.
-
公开(公告)号：WO2023023345A2
公开(公告)日：2023-02-23
申请号：PCT/US2022/040920
申请日：2022-08-19
IPC分类号： A61K41/00
摘要： The invention features methods of treating a subject receiving a cytopenia-associated myelofibrosis treatment by co-administering an activin receptor type II (ActRII) signaling inhibitor. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, or an ActRII ligand trap.
-
公开(公告)号：WO2022235620A1
公开(公告)日：2022-11-10
申请号：PCT/US2022/027399
申请日：2022-05-03
发明人： SEEHRA, Jasbir, S. , LACHEY, Jennifer , TSENG, Claire , FURUTANI, Elissa , ROVALDI, Christopher, R.
摘要： The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness or atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, pulmonary hypertension, and/or diseases and conditions that can be treated with erythropoietin or an erythropoiesis-stimulating agent.
-
公开(公告)号：WO2022099166A8
公开(公告)日：2022-05-12
申请号：PCT/US2021/058529
申请日：2021-11-09
IPC分类号： A61K38/00 , A61K31/497 , A61K31/535 , C12N5/02 , A61K31/44 , C12N5/0006
摘要： The invention features methods of treating or preventing the development of a cardiovascular-related disease by administering to a subject a BMP inhibitor or a hepcidin inhibitor, such as an ALK2 inhibitor. The methods comprising reducing cholesterol and/or reducing triglycerides in a subject in need thereof, wherein the cholesterol is low-density lipoprotein cholesterol. Further disclosed are different BMP inhibitors and hepcidin inhibitors that can be used.
-
公开(公告)号：WO2021189010A1
公开(公告)日：2021-09-23
申请号：PCT/US2021/023339
申请日：2021-03-19
摘要： The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.
-
公开(公告)号：WO2021189006A1
公开(公告)日：2021-09-23
申请号：PCT/US2021/023335
申请日：2021-03-19
摘要： The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and age-related and treatment-related metabolic disease.
-
公开(公告)号：WO2019140283A1
公开(公告)日：2019-07-18
申请号：PCT/US2019/013329
申请日：2019-01-11
IPC分类号： A61K38/17 , C07K14/00 , C07K14/51 , C07K14/47 , C07K14/495
摘要： The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and/or pulmonary hypertension.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.014 秒)
